HydroCision said early this month that it tapped former Smith & Nephew (NYSE:SNN) exec Alain Tranchemontagne as its new chief executive officer. Prior to joining Boston-based HydroCision, Tranchemontagne held a position as U.S. business commercial development senior VP at Smith & Nephew. Before joining Smith & Nephew, Tranchemontagne also held positions at Covidien in senior marketing roles […]
Gerresheimer taps Metzner as CFO | Personnel Moves – December 14, 2018
Gerresheimer said late last month that it tapped Dr. Bernd Metzner as its new chief financial officer, set to take position at the latest by July 1 next year. Prior to joining the Dusseldorf-based company, Metzner acted as CFO at Ströer, a position he took up in June 2014. He also held positions at Bayer […]
Aethlon Medical biz Exosome Science readies CTE biomarker trial of ex-NFL players
Aethlon Medical (NSDQ:AEMD) subsidiary Exosome Sciences said today it is launching a study of a biomarker candidate intended to detect and monitor chronic traumatic encephalopathy in a sample of retired NFL players. Screening is expected to begin in the coming weeks, Exosome Sciences said, and looks to enroll former NFL players at high risk of suffering from […]
Aethlon Medical wins FDA EAP designation for Hemopurifier
Aethlon Medical (NSDQ:AEMD) said today it received an Expedited Access Pathway designation for its Aethlon Hemopurifier designed for treating life-threatening viruses. The San Diego-based company said its Hemopurifier has been validated to capture a “broad spectrum of viruses that are highly glycosylated”, which includes lethal strains of pandemic influenza, mosquito-borne viruses and hemorrhagic viruses with no currently […]
Aethlon looks fast-track FDA nod for Hemopurifier blood filter through EAP
Aethlon Medical (NSDQ:AEMD) said today it is submitting an expedited access pathway application to the FDA seeking a breakthrough technology designation for its hemopurifier. Aethlon’s Hemopurifier device is a single-use, disposable cartridge designed to target and filter out viruses or tumor-secreted exosomes. Blood flows through the cartridge into nearly 3,000 hollow fibers with pores 250 nanometers in diameter. […]
Aethlon touts Hemopurifier feasibility study results
Aethlon Medical (NSDQ:AEMD) said today that it finished an FDA-approved feasibility study for its Hemopurifier device in health-compromised patients. Previously, the device was used under the FDA’s emergency-use authorization in patients infected with Hepatitis C, HIV and the Ebola virus. Aethlon’s Hemopurifier device is a single-use, disposable cartridge designed to target and filter out viruses or tumor-secreted […]
Tracking the neurodegenerative disease haunting American football
Aethlon Medical (NSDQ:AEMD) subsidiary Exosome Sciences said today that it plans to support a clinical trial involving retired NFL players to study a biomarker-based diagnostic to detect and monitor chronic traumatic encephalopathy in living people. CTE, a neurodegenerative disease found in American football players and people with a history of repetitive trauma to the head, […]
Aethlon’s blood filtration device as broad countermeasure for infectious diseases
In the midst of a devastating global crisis 2 years ago, a Ugandan physician was infected with Ebola in Sierra Leone as he was treating patients. He was hospitalized at the Frankfurt University Hospital and 12 days later he was unconscious, suffering from multiple organ failure. By the time Aethlon Medical (NSDQ:AEMD) got permission to use […]
Aethlon claims 50% blood serum clearance of Zika virus in 5 hours
Aethlon Medical (OTC:AEMD) said today that data from in vitro Zika virus studies of its Hemopurifier blood filter indicated a 50% clearance of the virus from human blood serum in 5 hours. The San Diego, Calif.-based company said the Zika studies, which were conducted with small-scale versions of the Hemopurifier, also reported a 95% clearance rate of […]
Aethlon Medical extends DARPA contract
Aethlon Medical (OTC:AEMD) said today it extended its contract with DARPA to develop a device to reduce the incidence of sepsis, a commonly fatal infection encountered by combat-injured soldiers. The contract with DARPA was originally inked in September 2011 and has been extended to its 5th year with Aethlon, the company said. The reward is a […]
Aethlon plans IDE, slims losses on Q1 report
Aethlon Medical (OTC:AEMD) yesterday said it plans to file for Investigative Device Exemption status for its HemoPurifier after the company’s contract with DARPA expires, and reports slimmed losses for the company and investors. In a quarterly earnings call, CEO Jim Joyce said this would be the company’s last year on contract with DARPA, with a caveat of a […]
- 1
- 2
- 3
- 4
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
YouTube